Another negative sepsis trial

Thymosin α1 is an immune modulating drug that was recently the subject of a large scale multi-center randomized clinical trial in China. Thymosin α1 modulates T-cell function and improves antigen presentation among other things. It had shown promise in multiple single center trials. The most recent by Wu et al. [ ]